<?xml version="1.0" encoding="UTF-8"?>
<!-- generator="wordpress.com" -->
<urlset xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd"
	xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
	xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"
	xmlns:image="http://www.google.com/schemas/sitemap-image/1.1"
	>
<url><loc>https://fdawatch.net/2026/10/26/whats-ahead-for-fda-and-medtech/</loc><news:news><news:publication><news:name>FDA Watch Podcast</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-10-26T18:44:35+00:00</news:publication_date><news:title>What&#8217;s Ahead for FDA and MedTech</news:title><news:keywords>FDA, regulation, FDA Watch, new episode, AI, artificial intelligence, technology, medical devices, user fees, CDRH, science, sports, religion, regulatory policy, internet, Michelle Tarver, QMSR, RAPID, medtech, MedTech Conference, AdvaMed, MDUFA, Philip Desjardins, Sean Boyd, Rusty Segan, advice</news:keywords></news:news><image:image><image:loc>https://fdawatch.net/wp-content/uploads/2025/08/fdawatch_artworkupdated8.5.jpg?w=150</image:loc></image:image></url></urlset>
